I thought it was interesting the CEO's comment during earnings call q&a that new gene therapies and specifically CAR-T therapy actually required more IG use as they need to suppress patient immunity during treatment to avoid cell rejection.
so rather than all these supposedly disruptive technologies threatening csl's business they're actually increasing demand.
CSL has more upside..., page-235
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$277.01 |
Change
-7.040(2.48%) |
Mkt cap ! $134.1B | |||
| Open | High | Low | Value | Volume |
| $280.67 | $281.07 | $275.01 | $254.8M | 915.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1140 | $277.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $277.08 | 312 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CSL (ASX) Chart |